Lenacapavir, the twice yearly injectable drug for HIV prevention, is now available in Nigeria at a reported cost of approximately ₦58,000 per year.
The long acting injection developed by Gilead Sciences and marketed internationally as Sunlenca is being introduced as a pre exposure prophylaxis PrEP option that requires just one subcutaneous shot every six months.
Nigeria currently has about 1.9 million people living with HIV, making it one of the countries with the highest HIV burdens globally.
Health experts say expanding access to more convenient prevention tools could play a critical role in reducing new infections.
Nigeria is among priority countries included in international access frameworks supporting wider distribution of the drug. The rollout is expected to integrate into existing national HIV prevention programs.
